i-Lumen Scientific
ADVANCING VISION

Restoring vision

Not Just Managing Disease

Series B Funding Round:
Seeking $28.0 M
Convertible Preferred Stock
Share price: US$1.35
Pre-money: US$31.6 Million
Post-money: US$76.9 Million

Age-related Macular Degeneration (AMD) Affects Central Vision

Dry AMD is a chronic disease of the macula (the central retina) that gradually reduces central vision over time. Intermediate AMD is the first stage of the disease to experience vision loss.



1 in 4 people

are affected by AMD and it is the leading cause of blindness in those over age 60.



Clinically Significant, Personally Meaningful

i-Lumen's proprietary dual waveform algorithm generates clinically significant vision improvement supporting a meaningful improvement in quality of life.



61.5%
with ≥10 letter improvement in BCVA by month 2

53.8%
maintained ≥10 letter improvement in BCVA through month 12

30.8%
with ≥15 letter improvement in BCVA at month 3

Restoring the Electrophysiology of the Retina

The i-Lumen AMD System is focused on restoring the electrophysiology of the retina through a novel, non-invasive bioelectric stimulation improving vision for those with intermediate to advanced dry Age-related Macular Degeneration (AMD).



$850M Strategic Acquisition Benchmark

In late 2025, Alcon completed a benchmark transaction, acquiring another pre-revenue, energy-based, device therapy to treat Dry-AMD for an estimated $850.0 million.

Clear Line-of-Sight to Strategic - Compelling Potential Return

i-Lumen's clinically meaningful outcomes have generated significant interest from leading ophthalmology companies, including Alcon, Johnson & Johnson, Bausch + Lomb, and Glaukos. The next major inflection point for i-Lumen is the release of primary endpoint data from its i-SIGHT2 Pivotal Study, currently targeted for early 2028. Projecting 10x to 12x return in 30 to 36 months.

John VeLure (CEO/President) - 952-240-6023 - jvelure@i-lumen.com